

Robert E J Ryder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9299892/publications.pdf>

Version: 2024-02-01

78
papers

1,462
citations

471509

17
h-index

345221

36
g-index

81
all docs

81
docs citations

81
times ranked

1597
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis of Adrenal Insufficiency. <i>Annals of Internal Medicine</i> , 2003, 139, 194.	3.9	266
2	Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. <i>Diabetes Care</i> , 2020, 43, 2153-2160.	8.6	111
3	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. <i>Diabetes Care</i> , 2017, 40, 813-820.	8.6	109
4	Colonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis. <i>British Journal of Clinical Pharmacology</i> , 1983, 16, 185-187.	2.4	104
5	New Treatment Options for Erectile Dysfunction in Patients with Diabetes Mellitus. <i>Drugs</i> , 2004, 64, 2667-2688.	10.9	86
6	Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 703-710.	4.4	83
7	"Natural family planning": effective birth control supported by the Catholic Church. <i>BMJ: British Medical Journal</i> , 1993, 307, 723-726.	2.3	82
8	Glycosylated Serum Albumin: An Intermediate Index of Diabetic Control. <i>Diabetes Care</i> , 1983, 6, 501-503.	8.6	77
9	Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter inhibitor. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 454-462.	4.4	44
10	Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. <i>Diabetic Medicine</i> , 2015, 32, 305-313.	2.3	35
11	The potential risks of pancreatitis and pancreatic cancer with GLP-1 based therapies are far outweighed by the proven and potential (cardiovascular) benefits. <i>Diabetic Medicine</i> , 2013, 30, 1148-1155.	2.3	32
12	Retinal vessel diameters and reactivity in diabetes mellitus and/or cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2017, 16, 56.	6.8	28
13	GLP-1 receptor agonists in type 2 diabetes - NICE guidelines versus clinical practice. <i>British Journal of Diabetes and Vascular Disease</i> , 2014, 14, 52.	0.6	25
14	Lactic Acidosis: High-Dose or Low-Dose Bicarbonate Therapy?. <i>Diabetes Care</i> , 1984, 7, 99-102.	8.6	23
15	An automated retinal image quality grading algorithm. , 2011, 2011, 5955-8.		22
16	Automated diagnosis of referable maculopathy in diabetic retinopathy screening. , 2011, 2011, 3375-8.		21
17	The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015, 109, 124-129.	2.8	19
18	Impotence in diabetes mellitus. <i>Diabetes/metabolism Reviews</i> , 1995, 11, 279-285.	0.3	18

#	ARTICLE	IF	CITATIONS
19	Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. <i>Diabetes Research and Clinical Practice</i> , 2011, 93, e87-e91.	2.8	18
20	The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multicentre observational study. <i>Diabetic Medicine</i> , 2014, 31, 403-411.	2.3	18
21	A UK nationwide study of people with type 1 diabetes admitted to hospital with COVID-19 infection. <i>Diabetologia</i> , 2021, 64, 1717-1724.	6.3	18
22	Ovarian ultrasonography highlights precision of symptoms of ovulation as markers of ovulation.. <i>BMJ: British Medical Journal</i> , 1986, 292, 1562-1562.	2.3	15
23	Nontraumatic rhabdomyolysis: an unusual complication of diabetic hyperosmolar nonketotic (HONK) state. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 200-200.	2.0	13
24	Safety and efficacy of liraglutide 1.2mg in patients with mild and moderate renal impairment: the ABCD nationwide liraglutide audit. <i>Practical Diabetes</i> , 2013, 30, 71.	0.3	13
25	Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence. <i>British Journal of Diabetes</i> , 2020, 20, 28-31.	0.2	13
26	Normo-osmolar, Nonketotic, Hyponatremic Diabetic Syndrome Associated with Impaired Renal Function. <i>Diabetes Care</i> , 1983, 6, 402-404.	8.6	10
27	Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME: the optimal combination may be metformin, pioglitazone and empagliflozin. <i>British Journal of Diabetes and Vascular Disease</i> , 2015, 15, 151.	0.6	10
28	Rehabilitation of pioglitazone. <i>British Journal of Diabetes and Vascular Disease</i> , 2015, 15, 46.	0.6	9
29	Pioglitazone and bladder cancer. <i>Lancet, The</i> , 2011, 378, 1544.	13.7	8
30	The United Kingdom's first NHS Endobarrier service for advanced diabetes: 1-year outcomes for all 62 treated patients. <i>British Journal of Diabetes</i> , 2019, 19, 110-117.	0.2	8
31	Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1398-1401.	4.4	8
32	Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter. <i>Diabetic Medicine</i> , 2015, 32, 438-439.	2.3	7
33	Predictors of diabetes-related distress before and after FreeStyle Libre use: Lessons from the Association of British Clinical Diabetologists nationwide study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2261-2268.	4.4	7
34	Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide-1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. <i>Diabetic Medicine</i> , 2012, 29, 690-692.	2.3	6
35	Pioglitazone: reports of its death are greatly exaggerated – it is alive and ready to resume saving lives. <i>Diabetic Medicine</i> , 2015, 32, e9-e15.	2.3	6
36	Pioglitazone: inexpensive; very effective at reducing HbA 1c ; no evidence of bladder cancer risk; plenty of evidence of cardiovascular benefit. <i>Diabetic Medicine</i> , 2019, 36, 1185-1186.	2.3	6

#	ARTICLE	IF	CITATIONS
37	Diabetes medications with cardiovascular protection in the wake of EXSCEL: is there a class effect for long-acting GLP-1 receptor agonists?. British Journal of Diabetes, 2017, 17, 131-133.	0.2	6
38	Insulin treatment and longer diabetes duration both predict poorer glycaemic response to liraglutide treatment in type 2 diabetes: the Association of British Clinical Diabetologists Nationwide Liraglutide Audit. British Journal of Diabetes and Vascular Disease, 2015, 15, 169.	0.6	6
39	Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?. British Journal of Diabetes, 2016, 16, 103.	0.2	6
40	FreeStyle Libre Flash Glucose Monitoring system for people with type 1 diabetes in the UK: a budget impact analysis. BMJ Open Diabetes Research and Care, 2022, 10, e002580.	2.8	6
41	ACE inhibitors and hypoglycaemia. Lancet, The, 1995, 346, 125-127.	13.7	5
42	Impotence in Diabetes. Trends in Endocrinology and Metabolism, 1997, 8, 98-101.	7.1	5
43	Inpatient diabetes: do-it-yourself electronic referral system to support and enhance the Think Glucose project. Practical Diabetes, 2014, 31, 194-196.	0.3	5
44	Diabetes medications with cardiovascular protection after HARMONY Outcomes and DECLARE-TIMI 58: could metformin, pioglitazone, SGLT2 inhibitors and long-acting GLP-1 receptor agonists complement each other to save lives by different mechanisms?. British Journal of Diabetes, 2019, 19, 1-5.	0.2	4
45	Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020. British Journal of Diabetes, 2020, 20, 85-88.	0.2	4
46	Duodenal-jejunal bypass liner for the treatment of type 2 diabetes and obesity: 3-year outcomes in the First National Health Service (NHS) EndoBarrier Service. Diabetic Medicine, 2022, , e14827.	2.3	4
47	The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis – what happens next? A personal viewpoint. Diabetic Medicine, 2013, 30, 1510-1511.	2.3	3
48	Real-world diabetes prevention: from theory to practice. Lancet Diabetes and Endocrinology, the, 2018, 6, 756-757.	11.4	3
49	An audit of people admitted to hospital with diabetes and coronavirus (SARS-CoV-2): data collection methods. The Association of British Clinical Diabetologists (ABCD) Nationwide Audit. British Journal of Diabetes, 2021, 21, 96-99.	0.2	3
50	Impaired Awareness of Hypoglycemia and Severe Hypoglycemia in Drivers With Diabetes: Insights From the Association of British Clinical Diabetologists Nationwide Audit. Diabetes Care, 2021, 44, e190-e191.	8.6	3
51	Bicarbonate Therapy and Lactic Acidosis: A Reply. Diabetes Care, 1984, 7, 510-510.	8.6	2
52	The metabolic response to glucagon and glucagon-like peptide in normal subjects and non insulin dependent diabetics.. British Journal of Clinical Pharmacology, 1986, 22, 325-329.	2.4	2
53	Pulmonary Embolism Masquerading as Stokes-Adams Attacks. Journal of the Royal Society of Medicine, 1987, 80, 460-461.	2.0	2
54	951 Endoscopic Proximal Intestinal Exclusion Can Improve Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients With Diabetes. Gastroenterology, 2016, 150, S1055-S1056.	1.3	2

#	ARTICLE	IF	CITATIONS
55	The United Kingdom's first NHS EndoBarrier service for long-standing poorly controlled type 2 diabetes and obesity: outcomes one year after EndoBarrier removal. <i>British Journal of Diabetes</i> , 2021, 21, 76-83.	0.2	2
56	Natural family planning. Author's reply.. <i>BMJ: British Medical Journal</i> , 1993, 307, 1360-1360.	2.3	2
57	What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?. <i>British Journal of Diabetes</i> , 2017, 17, 89.	0.2	2
58	Screening for diabetic retinopathy. <i>BMJ: British Medical Journal</i> , 1985, 290, 1349-1349.	2.3	1
59	Uncommon presentation of asymmetrical retinopathy in diabetes type 1. <i>Acta Ophthalmologica</i> , 2004, 82, 321-323.	0.3	1
60	ABCD position statement on GLP-1 based therapies and pancreatic damage. <i>Practical Diabetes</i> , 2013, 30, 388-391.	0.3	1
61	The effect of sodium-glucose link transporter 2 inhibitors on heart failure end points in people with type 2 diabetes mellitus: a systematic review and meta-analysis. <i>British Journal of Diabetes</i> , 0, , .	0.2	1
62	Maintenance of efficacy after duodenal-jejunal bypass liner explantation in the first NHS EndoBarrier service. <i>British Journal of Diabetes</i> , 2018, 18, 14-17.	0.2	1
63	Clinical use of Humulin R U-500 insulin in the UK: results of the first Association of British Clinical Diabetologists' U-500 audit. <i>British Journal of Diabetes</i> , 2016, 16, 185.	0.2	1
64	Diabetes medications with cardiovascular protection as we enter a new decade: can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives?. <i>British Journal of Diabetes</i> , 2020, 20, 5-8.	0.2	1
65	Detecting diabetic retinopathy.. <i>BMJ: British Medical Journal</i> , 1991, 302, 659-659.	2.3	0
66	Was it really pancreatitis from GLP-1 receptor agonist therapy?. <i>Practical Diabetes</i> , 2013, 30, 310-310.	0.3	0
67	OC-001...Efficacy, safety and tolerability outcomes of endoscopic proximal intestinal exclusion using endobarrier, 12 and 18 month data for the uk's first nhs endobarrier service for diabetes. , 2017, , .		0
68	Mohammad Afzal Mir. <i>BMJ: British Medical Journal</i> , 2019, , 14841.	2.3	0
69	Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement. <i>British Journal of Diabetes</i> , 2021, 21, 132-148.	0.2	0
70	Previous structured education attendance and the relationship with HbA1c and hypoglycaemia awareness in people living with type 1 diabetes mellitus using FreeStyle Libre: insights from the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. <i>British Journal of Diabetes</i> , 0, , .	0.2	0
71	ABCD now on N3: The ABCD nationwide exenatide QW audit. <i>British Journal of Diabetes and Vascular Disease</i> , 2014, 14, 40.	0.6	0
72	This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes. <i>British Journal of Diabetes</i> , 2016, 16, 88.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Bariatric surgery and surgical devices in obesity management. British Journal of Diabetes, 2016, 16, 156.	0.2	0
74	Reductions in alanine aminotransferase levels with liraglutide treatment are greatest in those with raised baseline levels and are independent of weight loss: real-world outcome data from the ABCD Nationwide Liraglutide Audit. British Journal of Diabetes, 2019, 19, 118-123.	0.2	0
75	Early impact of liraglutide in routine clinical use (ABCD nationwide liraglutide audit) on cardiovascular risk (UKPDS risk engine). British Journal of Diabetes, 2020, 20, 25-27.	0.2	0
76	The effect of dapagliflozin on alanine aminotransferase as a marker of liver inflammation: updated results from the ABCD dapagliflozin audit. British Journal of Diabetes, 2020, 20, 19-24.	0.2	0
77	Effects of canagliflozin are mostly observed at first follow-up, within 6 months of commencement: results for the ABCD canagliflozin audit. British Journal of Diabetes, 2020, 20, 113-116.	0.2	0
78	COVID-19 outcomes in people with diabetes in Wales: a secondary analysis of the ABCD audit. British Journal of Diabetes, 0, , .	0.2	0